News ANGN BIOM

Equities

ANGN

US03476J1079

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
10.3 ^USD	+6.74%		+13.81%	+3.00%

2023	Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	CI
2023	Angion Biomedia to Implement 10-for-1 Reverse Split	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Durable immunogenicity of ELI-002 2P in AMPLIFY-201: Lymph node targeted mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer	Apr. 08	PU
Elicio Therapeutics to Present Updated Clinical T Cell and Antigen Spreading Response Data from the Ongoing AMPLIFY-201 Phase 1 Study of ELI-002 and Preclinical Data on ELI-007 and ELI-008 at the AACR Annual Meeting	Apr. 05	AQ
Elicio Therapeutics Reports 2023 Financial Results and Provides Corporate Updates	Mar. 29	AQ
Elicio Therapeutics Announces $6.0 Million Private Placement Financing	Mar. 18	AQ
Elicio Therapeutics Announces Upcoming Presentations at the American Association for Cancer Research (AACR) Annual Meeting	Mar. 06	AQ
Elicio Therapeutics Announces Publication of Preclinical Data Demonstrating TCR-T Cell Therapy in Combination with Lymph Node-Targeted Amphiphile-Immunotherapy Enhanced Anti-Tumor Function and Eradicated Solid Tumors	Jan. 25	AQ
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference	Jan. 16	AQ
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002	Jan. 09	AQ
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference	Dec. 04	AQ
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates	Nov. 09	AQ
ANGN BIOM : Lymph Node Targeted AMP-peptide Vaccines Generate Functional T cell Immunity Against Mutant p53 and BRAF (SITC – Scientific Poster)	Nov. 02	PU
ANGN BIOM : ELI-002 Immunotherapy Induces Broad Polyfunctional T cell Responses in Subjects with High Relapse Risk KRAS Mutated Pancreatic Ductal Adenocarcinoma and Colorectal Cancer (SITC – Scientific Poster)	Nov. 02	PU
ANGN BIOM : Management Change - Form 8-K	23-10-12	PU
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting	23-10-11	GL
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer	23-09-27	GL
Elicio Therapeutics Receives $2.6 Million Grant from the Gastro-Intestinal (GI) Research Foundation to Fund Research for Two Therapeutic Cancer Vaccines	23-09-07	GL
Elicio Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference	23-09-06	GL
Elicio Therapeutics to Present Phase 1 Data on Cancer Vaccine Candidate, ELI-002, in Patients with High Relapse Risk Pancreatic and Colorectal Cancers at the AACR Special Conference on Pancreatic Cancer	23-09-05	GL
Angion Biomedica Corp. Announces Resignation of Assaf Segal from Its Board of Directors	23-08-30	CI
Elicio Therapeutics Announces Appointment of Megan Filoon as General Counsel and Dr. Thian Kheoh as Senior Vice President of Biometrics	23-08-28	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News ANGN BIOM

Equities

ANGN

US03476J1079

Summary

Filters